Newswise Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis
And guessing with a GLP-1 receptor agonist that controls blood sugar, appetite, and gastric emptying is not a risk worth taking
After administration of glucose at 50, 75, 100 and 125 mg, glucose and insulin levels rose in all three groups with peaks being observed after 30 min
Guideline on similar biological medicinal products
That backing could help turn a niche approach into a more mainstream option
Sedaghatian-type spondylometaphyseal dysplasia: a case of rapid demise with evidence of myocardial injury